Biotech | April 25, 2022
CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
New product line to address the challenge of restrictions on use of plastic straws
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
Subscribe To Our Newsletter & Stay Updated
